Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 140
Filtrar
1.
Microbiol Spectr ; 12(4): e0341023, 2024 Apr 02.
Artigo em Inglês | MEDLINE | ID: mdl-38376366

RESUMO

The nucleocapsid protein of SARS-CoV-2 plays significant roles in viral assembly, immune evasion, and viral stability. Due to its immunogenicity, high expression levels during COVID-19, and conservation across viral strains, it represents an attractive target for antiviral treatment. In this study, we identified and characterized a single-stranded DNA aptamer, N-Apt17, which effectively disrupts the liquid-liquid phase separation (LLPS) mediated by the N protein. To enhance the aptamer's stability, a circular bivalent form, cb-N-Apt17, was designed and evaluated. Our findings demonstrated that cb-N-Apt17 exhibited improved stability, enhanced binding affinity, and superior inhibition of N protein LLPS; thus, it has the potential inhibition ability on viral replication. These results provide valuable evidence supporting the potential of cb-N-Apt17 as a promising candidate for the development of antiviral therapies against COVID-19.IMPORTANCEVariants of SARS-CoV-2 pose a significant challenge to currently available COVID-19 vaccines and therapies due to the rapid epitope changes observed in the viral spike protein. However, the nucleocapsid (N) protein of SARS-CoV-2, a highly conserved structural protein, offers promising potential as a target for inhibiting viral replication. The N protein forms complexes with genomic RNA, interacts with other viral structural proteins during virion assembly, and plays a critical role in evading host innate immunity by impairing interferon production during viral infection. In this investigation, we discovered a single-stranded DNA aptamer, designated as N-Apt17, exhibiting remarkable affinity and specificity for the N protein. Notably, N-Apt17 disrupts the liquid-liquid phase separation (LLPS) of the N protein. To enhance the stability and molecular recognition capabilities of N-Apt17, we designed a circular bivalent DNA aptamer termed cb-N-Apt17. In both in vivo and in vitro experiments, cb-N-Apt17 exhibited increased stability, enhanced binding affinity, and superior LLPS disrupting ability. Thus, our study provides essential proof-of-principle evidence supporting the further development of cb-N-Apt17 as a therapeutic candidate for COVID-19.


Assuntos
COVID-19 , Proteínas do Nucleocapsídeo , Humanos , SARS-CoV-2/genética , DNA de Cadeia Simples/farmacologia , Vacinas contra COVID-19 , Antivirais/farmacologia
2.
Cytokine ; 172: 156406, 2023 12.
Artigo em Inglês | MEDLINE | ID: mdl-37879125

RESUMO

BACKGROUND: Tumor Necrosis Factor-α (TNF-α) is a pro-inflammatory factor that plays a pivotal role in psoriasis. Due to limitations of monoclonal antibody-based therapies, it is needed to discover new anti-TNF-α factors instead of usual anti-TNF-α monoclonal antibodies. Compared to antibodies, single-stranded DNA or RNA molecules named aptamers, have advantages such as time-saving, less risk for immunogenicity and cost-effectiveness. Therefore, the aim of the present study was to assess the therapeutic effects of T1-T4 dimer anti-TNF-ɑ ssDNA aptamer topical treatment in the imiquimod (IMQ)-induced psoriasis animal model. METHODS: 5% IMQ cream was prescribed on the right ear of BALB/c to induce psoriasis model. The hydrogel-containing anti-TNF-ɑ aptamer or treatment control aptamer (anti- Interleukin (IL)17A) was topically prescribed to the mice's ears 10 min before IMQ cream treatment. The psoriasis area severity index (PASI) score was used to evaluate psoriasis intensity. Histopathology analysis was done for mice ears sections. Mass, size, and cell number of mice spleens were measured. The IL-17 level was determined in culture supernatants of axillary lymph node cells using ELISA. The mRNA expression levels of IL-17A, IL-1ß, STAT3, and S100a9, were evaluated in mice treated ear with quantitative Real Time-PCR. RESULTS: The anti-TNF-ɑ ssDNA aptamer lower doses had significant decrease in IMQ-induced PASI score (p < 0.05). In addition, in these groups, the IL-17A, STAT3, and S100a9 mRNA levels were significantly lower than the IMQ group (p < 0.05). CONCLUSION: According to our findings, this aptamer seems to be a prospective candidate for treating psoriatic inflammation especially in lower concentrations.


Assuntos
Interleucina-17 , Psoríase , Animais , Camundongos , Imiquimode/uso terapêutico , Interleucina-17/genética , Interleucina-17/metabolismo , Inibidores do Fator de Necrose Tumoral/efeitos adversos , Camundongos Endogâmicos BALB C , DNA de Cadeia Simples/metabolismo , DNA de Cadeia Simples/farmacologia , DNA de Cadeia Simples/uso terapêutico , Psoríase/induzido quimicamente , Psoríase/tratamento farmacológico , Inflamação/patologia , Fator de Necrose Tumoral alfa/metabolismo , RNA Mensageiro/metabolismo , Modelos Animais de Doenças , Pele/metabolismo
3.
Comput Biol Chem ; 95: 107568, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34543910

RESUMO

This study was planned to in silico screening of ssDNA aptamer against Escherichia coli O157:H7 by combination of machine learning and the PseKNC approach. For this, firstly a total numbers of 47 validated ssDNA aptamers as well as 498 random DNA sequences were considered as positive and negative training data respectively. The sequences then converted to numerical vectors using PseKNC method through Pse-in-one 2.0 web server. After that, the numerical vectors were subjected to classification by the SVM, ANN and RF algorithms available in Orange 3.2.0 software. The performances of the tested models were evaluated using cross-validation, random sampling and ROC curve analyzes. The primary results demonstrated that the ANN and RF algorithms have appropriate performances for the data classification. To improve the performances of mentioned classifiers the positive training data was triplicated and re-training process was also performed. The results confirmed that data size improvement had significant effect on the accuracy of data classification especially about RF model. Subsequently, the RF algorithm with accuracy of 98% was selected for aptamer screening. The thermodynamics details of folding process as well as secondary structures of the screened aptamers were also considered as final evaluations. The results confirmed that the selected aptamers by the proposed method had appropriate structure properties and there is no thermodynamics limit for the aptamers folding.


Assuntos
Aptâmeros de Nucleotídeos/farmacologia , DNA de Cadeia Simples/farmacologia , Escherichia coli O157/efeitos dos fármacos , Aprendizado de Máquina , Aptâmeros de Nucleotídeos/química , Biologia Computacional , DNA de Cadeia Simples/química , Avaliação Pré-Clínica de Medicamentos , Termodinâmica
4.
ACS Appl Mater Interfaces ; 13(34): 40354-40364, 2021 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-34410099

RESUMO

Insulin resistance (IR) is one of the essential conditions in the development of type 2 diabetes mellitus (T2DM). IR occurs in hepatic cells when the insulin receptor substrate-1 (IRS-1)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway is downregulated; thus, activating this pathway can significantly improve insulin sensitivity and ameliorate T2DM. Tetrahedral framework nucleic acids (tFNAs), a DNA nanomaterial, are synthesized from four single-stranded DNA molecules. tFNAs possess excellent biocompatibility and good water solubility and stability. tFNAs can promote cell proliferation, cell autophagy, wound healing, and nerve regeneration by activating the PI3K/Akt pathway. Herein, we explore the effects and underlying mechanisms of tFNAs on IR. The results displayed that tFNAs could increase glucose uptake and ameliorate IR by activating the IRS-1/PI3K/Akt pathway in glucosamine (GlcN)-stimulated HepG2 cells. By employing a PI3K inhibitor, we confirmed that tFNAs reduce IR through the PI3K/Akt pathway. Moreover, tFNAs can promote hepatic cell proliferation and inhibit GlcN-induced cell apoptosis. In a T2DM mouse model, tFNAs reduce blood glucose levels and ameliorate hepatic IR via the PI3K/Akt pathway. Taken together, tFNAs can improve hepatic IR and alleviate T2DM through the PI3K/Akt pathway, making contribution to the potential application of tFNAs in T2DM.


Assuntos
DNA de Cadeia Simples/uso terapêutico , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Resistência à Insulina/fisiologia , Transdução de Sinais/efeitos dos fármacos , Animais , DNA de Cadeia Simples/química , DNA de Cadeia Simples/farmacologia , Diabetes Mellitus Experimental/patologia , Diabetes Mellitus Tipo 2/patologia , Células Hep G2 , Humanos , Hipoglicemiantes/química , Hipoglicemiantes/farmacologia , Proteínas Substratos do Receptor de Insulina/metabolismo , Fígado/efeitos dos fármacos , Fígado/patologia , Camundongos Endogâmicos C57BL , Conformação de Ácido Nucleico , Fosfatidilinositol 3-Quinase/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo
5.
ChemMedChem ; 16(12): 1986-1995, 2021 06 17.
Artigo em Inglês | MEDLINE | ID: mdl-33711198

RESUMO

Many essential enzymes in bacteria remain promising potential targets of antibacterial agents. In this study, we discovered that dequalinium, a topical antibacterial agent, is an inhibitor of Staphylococcus aureus primase DnaG (SaDnaG) with low-micromolar minimum inhibitory concentrations against several S. aureus strains, including methicillin-resistant bacteria. Mechanistic studies of dequalinium and a series of nine of its synthesized analogues revealed that these compounds are single-stranded DNA bisintercalators that penetrate a bacterium by compromising its membrane. The best compound of this series likely interacts with DnaG directly, inhibits both staphylococcal cell growth and biofilm formation, and displays no significant hemolytic activity or toxicity to mammalian cells. This compound is an excellent lead for further development of a novel anti-staphylococcal therapeutic.


Assuntos
Antibacterianos/farmacologia , DNA Primase/antagonistas & inibidores , DNA de Cadeia Simples/farmacologia , Desenvolvimento de Medicamentos , Inibidores Enzimáticos/farmacologia , Staphylococcus aureus/efeitos dos fármacos , Antibacterianos/síntese química , Antibacterianos/química , Linhagem Celular , DNA Primase/metabolismo , DNA de Cadeia Simples/síntese química , DNA de Cadeia Simples/química , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/química , Humanos , Testes de Sensibilidade Microbiana , Staphylococcus aureus/enzimologia
6.
Mol Biol Rep ; 48(1): 139-146, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33400073

RESUMO

Aptamers as potential alternatives for antibodies could be employed against hepatitis B surface antigen (HBsAg), the great hallmark and first serological marker in HBV, for further theragnostic applications. Therefore, isolation HBsAg specific aptamer was performed in this study with a modified Cell-SELEX method. HEK293T overexpressing HBsAg and HEK293T as target and control cells respectively, were incubated with single-stranded rounds of DNA library during six SELEX and Counter SELEX rounds. Here, we introduced the new modified Cell-SELEX using deoxyribonuclease I digestion to separate single stranded DNA aptamers against the HBsAg. Characterization and evaluation of selected sequences were performed using flow cytometry analysis. The results led to isolation of 15 different ssDNA clones in six rounds of selection which were categorized to four clusters based on common structural motifs. The evaluation of SELEX progress showed growth in aptamer affinity with increasing in the cycle number. Taken together, the application of modified cell-SELEX demonstrated the isolation of HBsAg-specific ssDNA aptamers with proper affinity. Modified cell-SELEX as an efficient method can shorten the selection procedure and increase the success rate while the benefits of cell-based SELEX will be retained. Selected aptamers could be applied in purification columns, diagnostic kits, and drug delivery system against HBV-related liver cancer.


Assuntos
Aptâmeros de Nucleotídeos/farmacologia , Antígenos de Superfície da Hepatite B/isolamento & purificação , Hepatite B/genética , Neoplasias Hepáticas/tratamento farmacológico , Técnica de Seleção de Aptâmeros , DNA de Cadeia Simples/genética , DNA de Cadeia Simples/farmacologia , Desoxirribonuclease I/genética , Sistemas de Liberação de Medicamentos , Citometria de Fluxo , Células HEK293 , Hepatite B/imunologia , Hepatite B/virologia , Antígenos de Superfície da Hepatite B/genética , Antígenos de Superfície da Hepatite B/imunologia , Humanos , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/imunologia , Neoplasias Hepáticas/patologia
7.
Nucleic Acid Ther ; 30(6): 365-378, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32881630

RESUMO

C promoter binding factor 1 (CBF1) (alias RBPJ) is a critical transcription factor involved in Notch signaling. The activation of Notch signaling through CBF1 maintains the angiostatic state of endothelial cells suppressing angiogenesis, that is, the formation of new blood vessels. Vascular endothelial growth factor (VEGF) induces angiogenesis by promoting the proteasomal degradation of CBF1, in addition to endothelial cell proliferation. To date, angiogenic inhibitors targeting VEGF have been successfully used in clinics for cancer and age-related macular degeneration. Most antiangiogenic drugs, however, only target VEGF or VEGF receptors. In this study, to expand the repertoire of antiangiogenic therapeutics, we developed 15 single-stranded deoxyribonucleic acid (ssDNA) aptamers capable of binding to CBF1 with high affinity (Kd; 10-300 nM). To this end, systematic evolution of ligands by the exponential enrichment (SELEX) method was applied. One of the CBF1-binding ssDNA aptamers, Apt-3, inhibited angiogenesis through the activation of Notch signaling in vitro. We found that Apt-3 directly interacted with the LAG1 domain of CBF1. We suggest that the Apt-3 ssDNA aptamer may contribute to the development of a novel angiogenic inhibitor, which does not target VEGF.


Assuntos
Inibidores da Angiogênese/farmacologia , Proteína de Ligação a Sequências Sinal de Recombinação J de Imunoglobina/genética , Neovascularização Patológica/tratamento farmacológico , Técnica de Seleção de Aptâmeros , DNA de Cadeia Simples/genética , DNA de Cadeia Simples/farmacologia , Humanos , Proteína de Ligação a Sequências Sinal de Recombinação J de Imunoglobina/antagonistas & inibidores , Neoplasias/tratamento farmacológico , Neoplasias/genética , Neovascularização Patológica/genética , Ligação Proteica/efeitos dos fármacos , Receptores Notch/genética , Receptores de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores , Receptores de Fatores de Crescimento do Endotélio Vascular/genética , Transdução de Sinais/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Fator A de Crescimento do Endotélio Vascular/genética
8.
Cardiovasc Drugs Ther ; 34(4): 475-485, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32415571

RESUMO

BACKGROUND: Proprotein convertase subtilisin/kexin 9 (PCSK9) serves a key regulatory function in the metabolism of low-density lipoprotein (LDL)-cholesterol (LDL-C) through interaction with the LDL receptor (LDLR) followed by its destruction that results in the elevation of the plasma levels of LDL-C. The aims of the present study were to separate and select a number of single-stranded DNA (ssDNA) aptamers against PCSK9 from a library pool (n > 1012) followed by their characterization. METHODS: The aptamers obtained from the DNA-PCSK9 complexes which presented the highest affinity against PCSK9 were separated and selected using capillary electrophoresis evolution of ligands by exponential enrichment (CE-SELEX). The selected aptamers were amplified and cloned into a T/A vector. The plasmids from the positive clones were extracted and sequenced. The Mfold web server was used to predict the secondary structure of the aptamers. RESULTS: Following three rounds of CE-SELEX, the identified anti-PCSK9 ssDNA aptamers, namely aptamer 1 (AP-1) and aptamer 2 (AP-2), presented half maximal inhibitory concentrations of 325 and 327 nM, lowest dissociation constants of 294 and 323 nM, and most negative Gibbs free energy values of - 9.17 and - 8.28 kcal/mol, respectively. CONCLUSION: The results indicated that the selected aptamers (AP-1 and AP-2) induced potent inhibitory effects against PCSK9. Further in vivo studies demand to find out AP-1 and AP-2 aptamers as suitable candidates, instead of antibodies, for using in therapeutic purposes in patients with hypercholesterolemia and cardiovascular disease.


Assuntos
Aptâmeros de Nucleotídeos/farmacologia , DNA de Cadeia Simples/farmacologia , Biblioteca Gênica , Hipercolesterolemia/tratamento farmacológico , Inibidores de PCSK9 , Técnica de Seleção de Aptâmeros , Anticolesterolemiantes , Aptâmeros de Nucleotídeos/genética , Aptâmeros de Nucleotídeos/metabolismo , DNA de Cadeia Simples/genética , DNA de Cadeia Simples/metabolismo , Humanos , Hipercolesterolemia/enzimologia , Hipercolesterolemia/genética , Terapia de Alvo Molecular , Pró-Proteína Convertase 9/genética , Pró-Proteína Convertase 9/metabolismo
9.
PLoS One ; 15(5): e0226791, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32374764

RESUMO

Over the past two decades, measurements of carbon nanotube toxicity and biodistribution have yielded a wide range of results. Properties such as nanotube type (single-walled vs. multi-walled), purity, length, aggregation state, and functionalization, as well as route of administration, greatly affect both the biocompatibility and biodistribution of carbon nanotubes. These differences suggest that generalizable conclusions may be elusive and that studies must be material- and application-specific. Here, we assess the short- and long-term biodistribution and biocompatibility of a single-chirality DNA-encapsulated single-walled carbon nanotube complex upon intravenous administration that was previously shown to function as an in-vivo reporter of endolysosomal lipid accumulation. Regarding biodistribution and fate, we found bulk specificity to the liver and >90% signal attenuation by 14 days in mice. Using near-infrared hyperspectral microscopy to measure single nanotubes, we found low-level, long-term persistence in organs such as the heart, liver, lung, kidney, and spleen. Measurements of histology, animal weight, complete blood count; biomarkers of organ function all suggest short- and long-term biocompatibility. This work suggests that carbon nanotubes can be used as preclinical research tools in-vivo without affecting acute or long-term health.


Assuntos
Materiais Biocompatíveis/farmacologia , Biomarcadores/sangue , Nanotecnologia , Nanotubos de Carbono/efeitos adversos , Animais , Materiais Biocompatíveis/efeitos adversos , Materiais Biocompatíveis/química , DNA de Cadeia Simples/química , DNA de Cadeia Simples/farmacologia , Endossomos/efeitos dos fármacos , Humanos , Fígado/efeitos dos fármacos , Pulmão/efeitos dos fármacos , Camundongos , Nanotubos de Carbono/química , Imagem Óptica , Baço/efeitos dos fármacos , Baço/metabolismo , Distribuição Tecidual/efeitos dos fármacos
10.
Org Biomol Chem ; 17(43): 9435-9441, 2019 11 06.
Artigo em Inglês | MEDLINE | ID: mdl-31603457

RESUMO

To restrict pathogens, in a normal human cell, APOBEC3 enzymes mutate cytosine to uracil in foreign single-stranded DNAs. However, in cancer cells, APOBEC3B (one of seven APOBEC3 enzymes) has been identified as the primary source of genetic mutations. As such, APOBEC3B promotes evolution and progression of cancers and leads to development of drug resistance in multiple cancers. As APOBEC3B is a non-essential protein, its inhibition can be used to suppress emergence of drug resistance in existing anti-cancer therapies. Because of the vital role of APOBEC3 enzymes in innate immunity, selective inhibitors targeting only APOBEC3B are required. Here, we use the discriminative properties of wild-type APOBEC3A, APOBEC3B and APOBEC3G to deaminate different cytosines in the CCC-recognition motif in order to best place the cytidine analogue 2'-deoxyzebularine (dZ) in the CCC-motif. Using several APOBEC3 variants that mimic deamination patterns of wild-type enzymes, we demonstrate that selective inhibition of APOBEC3B in preference to other APOBEC3 constructs is feasible for the dZCC motif. This work is an important step towards development of in vivo tools to inhibit APOBEC3 enzymes in living cells by using short, chemically modified oligonucleotides.


Assuntos
Citidina Desaminase/antagonistas & inibidores , Citidina/análogos & derivados , DNA de Cadeia Simples/farmacologia , Inibidores Enzimáticos/farmacologia , Proteínas/antagonistas & inibidores , Linhagem Celular , Citidina/química , Citidina/farmacologia , Citidina Desaminase/metabolismo , DNA de Cadeia Simples/química , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/química , Humanos , Estrutura Molecular , Proteínas/metabolismo
11.
Curr Protein Pept Sci ; 20(11): 1060-1068, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31470785

RESUMO

Single stranded microbial DNA fragments with unmethylated deoxycytidylyldeoxyguanosine dinucleotide (CpG) motifs are interpreted as danger signals by the innate immune system via recognition by the Toll-like Receptor 9 (TLR9). Their synthetic analogues, Oligodeoxynucleotides (ODN) comprise a promising class of immune modulators with potential applications in the treatment of multiple diseases, such as cancer, autoimmune diseases or allergy. ODN molecules contain a core hexamer sequence, which is species specific consisting of GACGTT and AACGT for mouse and GTCGTT in humans. Assessment of structural features of different type of ODNs is highly challenging. NMR spectroscopic insights were gained for a short, single CpG motif containing ODN 1668. The structural basis of ODN recognition by TLR9 recently started to unravel as crystal structures of TLR9 orthologues in complex with ODN 1668 were solved. Systematic investigations of ODN sequences revealed that ODNs with a single CpG motif are capable of activating mouse TLR9, but two closely positioned CpG motifs are necessary for activation of human TLR9. Furthermore, longer ODNs with TCC and TCG sequences at the 5' end were shown to activate TLR9 with higher efficiency. It was revealed that 5'-xCx motif containing short ODNs (sODN) are able to augment the immune response of short, single CpG containing ODNs, which are incapable of activating of TLR9 alone. All these observations pointed to the existence of a second binding site on TLR9, which was characterized in crystal structures that delivered further insights of the nucleic acid recognition of the innate immune system by TLR9.


Assuntos
DNA de Cadeia Simples/química , DNA de Cadeia Simples/farmacologia , Fatores Imunológicos/química , Fatores Imunológicos/farmacologia , Oligodesoxirribonucleotídeos/metabolismo , Receptor Toll-Like 9/metabolismo , Sequência de Bases , DNA de Cadeia Simples/metabolismo , Humanos , Fatores Imunológicos/metabolismo , Oligodesoxirribonucleotídeos/química , Oligodesoxirribonucleotídeos/genética
12.
Methods Mol Biol ; 2054: 223-241, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31482459

RESUMO

Cell-SELEX is a live cell-based in vitro selection method that generates functional oligonucleotides, or aptamers. Often referenced as the chemist's antibody, aptamers bind to select targets with high affinity and can be utilized in a number of applications, including biomedicine, bioimaging, and biosensing. Here we describe the cell-SELEX technique and discuss this methodology's unique merit(s)-namely the ability to isolate highly selective aptamer panels with no prior knowledge of cellular signatures. This strategy thus presents as a technology that has the potential to enhance the precision of molecular medicine and targeted therapeutics.


Assuntos
Aptâmeros de Nucleotídeos/isolamento & purificação , DNA de Cadeia Simples/isolamento & purificação , Técnica de Seleção de Aptâmeros/métodos , Aptâmeros de Nucleotídeos/genética , Aptâmeros de Nucleotídeos/farmacologia , Técnicas de Cultura de Células/métodos , Linhagem Celular , DNA de Cadeia Simples/genética , DNA de Cadeia Simples/farmacologia , Humanos , Terapia de Alvo Molecular/métodos , Medicina de Precisão/métodos , Técnica de Seleção de Aptâmeros/instrumentação , Nanomedicina Teranóstica/métodos
13.
Mikrochim Acta ; 186(8): 566, 2019 07 24.
Artigo em Inglês | MEDLINE | ID: mdl-31338605

RESUMO

The presence or absence and nature of the free patchy ends in DNA sequences has a decisive effect on the performance of colorimetric sensors based on the use of gold nanoparticles (Au NPs). The authors have designed two unmodified gene probes (probe 1: a 19-mer; probe 2: an 18-mer). They are complementary to either half of a 37-mer target derived from the conserved region of Hepatitis C Virus (HCV) RNA. Each probe has further been modified with 10-mer poly(A) and thiol-functionalized 10-mer poly(A) at the 5' positions. Nine combinations of probe and HCV RNA were then designed to investigate the effect of free patchy ends on the stability of citrate-modified Au NPs against salt-induced aggregation which lead to color change from red to blue. The aggregation of Au NPs can be monitored by ratiometric spectroscopy at wavelengths of 520 and 700 nm. The differentiation between HCV RNA and control has also been studied by varying the concentration of probe and analyte. The particle size and zeta potentials were determined before and after aggregation. It is demonstrated that the change in surface charge density of the Au NPs governs the critical coagulation concentration of NaCl. The method presented here can be used to quantify HCV RNA in the 370 nM to 3 µM concentration range, and the detection limit is 500 nM. The results obtained with Au NPs that are chemically non-conjugated with the oligonucleotides have been found to be valuable in rationally devising the design rules for rapid and efficient colorimetric sensing of oligonucleotides. Graphical abstract Schematic representation of the nine combinatorial pairs of oligonucleotides that vary in the length of patchy ends and their position to unearth their effect in rapid gold nanoparticle-based colorimetric gene sensing without time-consuming and expensive thiol-conjugation step.


Assuntos
Técnicas Biossensoriais/métodos , Colorimetria/métodos , Hepacivirus/genética , Nanopartículas Metálicas/química , RNA Viral/análise , DNA/metabolismo , DNA/farmacologia , DNA de Cadeia Simples/metabolismo , DNA de Cadeia Simples/farmacologia , Ouro/química , Tamanho da Partícula , Sondas RNA/química , Sondas RNA/metabolismo
14.
Chembiochem ; 20(9): 1139-1144, 2019 05 02.
Artigo em Inglês | MEDLINE | ID: mdl-30610755

RESUMO

Programmable DNA nanostructures are a new class of biocompatible, nontoxic nanomaterials. Nevertheless, their application in the field of biomedical research is still in its infancy, especially as drug delivery vehicles for gene therapy. In this study, a GTPase Rab26 was investigated as a new potential therapeutic target using a precisely tailored DNA nanoprism for targeted lung cancer therapy. Specifically, a DNA nanoprism platform with tunable targeting and siRNA loading capability is designed and synthesized. The as-prepared DNA prisms were decorated with two functional units: a Rab26 siRNA as the drug and MUC-1 aptamers as a targeting moiety for non-small cell lung cancer. The number and position of both siRNA and MUC-1 aptamers can be readily tuned by switching two short, single-stranded DNA. Native polyacrylamide gel electrophoresis (PAGE) and dynamic light scattering technique (DLS) demonstrate that all nanoprisms with different functionalities are self-assembled with high yield. It is also found that the cellular uptake of DNA prisms is proportional to the aptamer number on each nanoprism, and the as-prepared DNA nanoprism show excellent anti-cancer activities and targeting capability. This study suggests that by careful design, self-assembled DNA nanostructures are highly promising, customizable, multifunctional nanoplatforms for potential biomedical applications, such as personalized precision therapy.


Assuntos
Antineoplásicos/farmacologia , Aptâmeros de Nucleotídeos/farmacologia , DNA de Cadeia Simples/farmacologia , Nanoestruturas/química , RNA Interferente Pequeno/farmacologia , Células A549 , Antineoplásicos/química , Aptâmeros de Nucleotídeos/química , Aptâmeros de Nucleotídeos/genética , DNA de Cadeia Simples/química , DNA de Cadeia Simples/genética , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Hibridização de Ácido Nucleico , Estudo de Prova de Conceito , RNA Interferente Pequeno/química , RNA Interferente Pequeno/genética , Proteínas rab de Ligação ao GTP/genética
15.
Adv Biosyst ; 3(4): e1800321, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-32627429

RESUMO

Nanostructured biomaterials are extensively explored in clinical imaging and in gene/drug delivery applications. However, limited studies are performed that examine the influence that nanomaterials may have on cell behavior over long time scales at nonlethal concentrations. This study is designed to investigate whether carbon nanotubes are able to augment cell behavior at low concentrations. Single-walled carbon nanotubes are introduced to neural stem cells at different stages of differentiation at concentrations as low as 5 ng mL-1 . Results demonstrate that in this particular cell model, nanotube uptake is mediated by endocytosis. Differentiation is augmented, especially when nanotubes are introduced to cells in an actively dividing state. Significant increases in neuronal cell population are observed over the control specimens. While the mechanisms behind this observation are yet unknown, this study demonstrates that low concentrations of internalized nanomaterials can significantly alter the differentiation profile of a stem cell line.


Assuntos
Diferenciação Celular/efeitos dos fármacos , DNA de Cadeia Simples , Nanotubos de Carbono/química , Células-Tronco Neurais , Animais , Linhagem Celular , DNA de Cadeia Simples/química , DNA de Cadeia Simples/farmacocinética , DNA de Cadeia Simples/farmacologia , Camundongos , Células-Tronco Neurais/citologia , Células-Tronco Neurais/efeitos dos fármacos , Células-Tronco Neurais/metabolismo
16.
Biochemistry ; 58(5): 391-400, 2019 02 05.
Artigo em Inglês | MEDLINE | ID: mdl-30418757

RESUMO

APOBEC3 enzymes form part of the innate immune system by deaminating cytosine to uracil in single-stranded DNA (ssDNA) and thereby preventing the spread of pathogenic genetic information. However, APOBEC mutagenesis is also exploited by viruses and cancer cells to increase rates of evolution, escape adaptive immune responses, and resist drugs. This raises the possibility of APOBEC3 inhibition as a strategy for augmenting existing antiviral and anticancer therapies. Here we show that, upon incorporation into short ssDNAs, the cytidine nucleoside analogue 2'-deoxyzebularine (dZ) becomes capable of inhibiting the catalytic activity of selected APOBEC variants derived from APOBEC3A, APOBEC3B, and APOBEC3G, supporting a mechanism in which ssDNA delivers dZ to the active site. Multiple experimental approaches, including isothermal titration calorimetry, fluorescence polarization, protein thermal shift, and nuclear magnetic resonance spectroscopy assays, demonstrate nanomolar dissociation constants and low micromolar inhibition constants. These dZ-containing ssDNAs constitute the first substrate-like APOBEC3 inhibitors and, together, comprise a platform for developing nucleic acid-based inhibitors with cellular activity.


Assuntos
Desaminase APOBEC-3G/antagonistas & inibidores , Citidina Desaminase/antagonistas & inibidores , Citidina/análogos & derivados , DNA de Cadeia Simples/farmacologia , Inibidores Enzimáticos/farmacologia , Proteínas/antagonistas & inibidores , Desaminase APOBEC-3G/metabolismo , Citidina/química , Citidina/farmacologia , Citidina Desaminase/metabolismo , DNA de Cadeia Simples/química , Inibidores Enzimáticos/química , Humanos , Antígenos de Histocompatibilidade Menor/metabolismo , Proteínas/metabolismo
17.
Sci Rep ; 8(1): 15841, 2018 10 26.
Artigo em Inglês | MEDLINE | ID: mdl-30367171

RESUMO

Recognition of nucleic acids by endosomal Toll-like receptors (TLR) is essential to combat pathogens, but requires strict control to limit inflammatory responses. The mechanisms governing this tight regulation are unclear. We found that single-stranded oligonucleotides (ssON) inhibit endocytic pathways used by cargo destined for TLR3/4/7 signaling endosomes. Both ssDNA and ssRNA conferred the endocytic inhibition, it was concentration dependent, and required a certain ssON length. The ssON-mediated inhibition modulated signaling downstream of TLRs that localized within the affected endosomal pathway. We further show that injection of ssON dampens dsRNA-mediated inflammatory responses in the skin of non-human primates. These studies reveal a regulatory role for extracellular ssON in the endocytic uptake of TLR ligands and provide a mechanistic explanation of their immunomodulation. The identified ssON-mediated interference of endocytosis (SOMIE) is a regulatory process that temporarily dampens TLR3/4/7 signaling, thereby averting excessive immune responses.


Assuntos
Clatrina/metabolismo , Endocitose/efeitos dos fármacos , Oligonucleotídeos/farmacologia , Receptor 3 Toll-Like/metabolismo , Receptor 4 Toll-Like/metabolismo , Receptor 7 Toll-Like/metabolismo , Animais , Células Cultivadas , Quimiocinas/metabolismo , Citocinas/metabolismo , DNA de Cadeia Simples/farmacologia , Endossomos/metabolismo , Humanos , Leucócitos Mononucleares/citologia , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/metabolismo , Macaca fascicularis , Poli I-C/farmacologia , Transdução de Sinais/efeitos dos fármacos , Pele/metabolismo , Pele/patologia , Receptor 3 Toll-Like/antagonistas & inibidores , Receptor 4 Toll-Like/antagonistas & inibidores , Receptor 7 Toll-Like/antagonistas & inibidores
18.
Sci Rep ; 8(1): 1332, 2018 01 22.
Artigo em Inglês | MEDLINE | ID: mdl-29358698

RESUMO

CRISPR/Cas9 has recently been developed as an efficient genome engineering tool. The rabbit is a suitable animal model for studies of metabolic diseases. In this study, we generated ATP7B site-directed point mutation rabbits to simulate a major mutation type in Asians (p. Arg778Leu) with Wilson disease (WD) by using the CRISPR/Cas9 system combined with single-strand DNA oligonucleotides (ssODNs). The efficiency of the precision point mutation was 52.94% when zygotes were injected 14 hours after HCG treatment and was significantly higher than that of zygotes injected 19 hours after HCG treatment (14.29%). The rabbits carrying the allele with mutant ATP7B died at approximately three months of age. Additionally, the copper content in the livers of rabbits at the onset of WD increased nine-fold, a level similar to the five-fold increase observed in humans with WD. Thus, the efficiency of precision point mutations increases when RNAs are injected into zygotes at earlier stages, and the ATP7B mutant rabbits are a potential model for human WD disease with applications in pathological analysis, clinical treatment and gene therapy research.


Assuntos
ATPases Transportadoras de Cobre/genética , Modelos Animais de Doenças , Degeneração Hepatolenticular/genética , Oligodesoxirribonucleotídeos/administração & dosagem , Mutação Puntual , Animais , Sistemas CRISPR-Cas , Cobre/análise , DNA de Cadeia Simples/administração & dosagem , DNA de Cadeia Simples/farmacologia , Humanos , Fígado/química , Microinjeções , Mutagênese Sítio-Dirigida , Oligodesoxirribonucleotídeos/farmacologia , Coelhos , Zigoto/química , Zigoto/crescimento & desenvolvimento
19.
Sci Rep ; 7: 45377, 2017 03 30.
Artigo em Inglês | MEDLINE | ID: mdl-28358012

RESUMO

The transcription factor FOXM1 binds to its consensus sequence at promoters through its DNA binding domain (DBD) and activates proliferation-associated genes. The aberrant overexpression of FOXM1 correlates with tumorigenesis and progression of many cancers. Inhibiting FOXM1 transcriptional activities is proposed as a potential therapeutic strategy for cancer treatment. In this study, we obtained a FOXM1-specific single stranded DNA aptamer (FOXM1 Apt) by SELEX with a recombinant FOXM1 DBD protein as the target of selection. The binding of FOXM1 Apt to FOXM1 proteins were confirmed with electrophoretic mobility shift assays (EMSAs) and fluorescence polarization (FP) assays. Phosphorthioate-modified FOXM1 Apt (M-FOXM1 Apt) bound to FOXM1 as wild type FOXM1 Apt, and co-localized with FOXM1 in nucleus. M-FOXM1-Apt abolished the binding of FOXM1 on its consensus binding sites and suppressed FOXM1 transcriptional activities. Compared with the RNA interference of FOXM1 in cancer cells, M-FOXM1 Apt repressed cell proliferation and the expression of FOXM1 target genes without changing FOXM1 levels. Our results suggest that the obtained FOXM1 Apt could be used as a probe for FOXM1 detection and an inhibitor of FOXM1 transcriptional functions in cancer cells at the same time, providing a potential reagent for cancer diagnosis and treatment in the future.


Assuntos
Aptâmeros de Nucleotídeos/farmacologia , Proteína Forkhead Box M1/antagonistas & inibidores , Transcrição Gênica/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , DNA de Cadeia Simples/farmacologia , Células HEK293 , Humanos , Neoplasias/genética , Neoplasias/metabolismo , Técnica de Seleção de Aptâmeros/métodos
20.
Nucleic Acid Ther ; 27(3): 176-181, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28080251

RESUMO

The bacterial cell wall presents a barrier to the uptake of unmodified synthetic antisense oligonucleotides, such as peptide nucleic acids, and so is one of the greatest obstacles to the development of their use as therapeutic anti-bacterial agents. Cell-penetrating peptides have been covalently attached to antisense agents, to facilitate penetration of the bacterial cell wall and deliver their cargo into the cytoplasm. Although they are an effective vector for antisense oligonucleotides, they are not specific for bacterial cells and can exhibit growth inhibitory properties at higher doses. Using a bacterial cell growth assay in the presence of cefotaxime (CTX 16 mg/L), we have developed and evaluated a self-assembling non-toxic DNA tetrahedron nanoparticle vector incorporating a targeted anti-blaCTX-M-group 1 antisense peptide nucleic acid (PNA4) in its structure for penetration of the bacterial cell wall. A dose-dependent CTX potentiating effect was observed when PNA4 (0-40 µM) was incorporated into the structure of a DNA tetrahedron vector. The minimum inhibitory concentration (to CTX) of an Escherichia coli field isolate harboring a plasmid carrying blaCTX-M-3 was reduced from 35 to 16 mg/L in the presence of PNA4 carried by the DNA tetrahedron vector (40 µM), contrasting with no reduction in MIC in the presence of PNA4 alone. No growth inhibitory effects of the DNA tetrahedron vector alone were observed.


Assuntos
Peptídeos Penetradores de Células/farmacologia , DNA de Cadeia Simples/farmacologia , Proteínas de Escherichia coli/efeitos dos fármacos , Escherichia coli/efeitos dos fármacos , Oligonucleotídeos Antissenso/farmacologia , Ácidos Nucleicos Peptídicos/farmacologia , beta-Lactamases/efeitos dos fármacos , Antibacterianos/farmacologia , Cefotaxima/farmacologia , Parede Celular/química , DNA de Cadeia Simples/química , Relação Dose-Resposta a Droga , Sistemas de Liberação de Medicamentos/tendências , Testes de Sensibilidade Microbiana , Nanopartículas/química , Oligonucleotídeos Antissenso/química , Ácidos Nucleicos Peptídicos/química , Plasmídeos/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...